Biotechnology Healthcare - November/December 2008 - (Page 19) “In a lot of cases,” says Lance Wallach, president of VEBA Plan LLC, “there is more flexibility in how VEBAs are structured to pay costs, so they may be more likely to pay for more expensive treatment, such as biotechnology.”
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.